Yanan Zhu
Stock Analyst at Wells Fargo
(4.63)
# 889
Out of 4,468 analysts
418
Total ratings
41%
Success rate
17.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintained: Buy | $100 | $81.80 | +22.25% | 43 | Jun 25, 2026 | |
| SGMOQ Sangamo Therapeutics, Inc. | Rated: Hold | n/a | $0.0749 | - | 22 | Jun 25, 2026 | |
| ENGN enGene Therapeutics | Rated: Hold | $2 | $1.78 | +12.36% | 18 | Jun 15, 2026 | |
| BEAM Beam Therapeutics | Maintained: Buy | $70 | $34.79 | +101.21% | 22 | Jun 4, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $15 | $17.56 | -14.58% | 26 | May 12, 2026 | |
| MGX Metagenomi Therapeutics | Maintained: Buy | $12 → $9 | $1.26 | +614.29% | 14 | May 11, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | $95 → $105 | $86.49 | +21.40% | 2 | May 7, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Buy | $38 | $19.28 | +97.10% | 15 | May 7, 2026 | |
| ONC BeOne Medicines AG | Maintained: Buy | $400 | $297.65 | +34.39% | 2 | May 7, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $75 | $60.08 | +24.83% | 15 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $50 → $90 | $86.63 | +3.89% | 14 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $34.83 | +29.20% | 4 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $6.53 | +68.45% | 27 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $13.65 | +83.15% | 1 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $3.65 | +9.59% | 25 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $15 → $60 | $41.81 | +43.51% | 27 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $7.28 | +174.73% | 26 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $4.31 | +224.83% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.58 | +216.46% | 19 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $3.30 | +21.21% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 | $2.92 | -14.38% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $0.1 | $0.0001 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1 | $0.039 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.78 | n/a | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $37.93 | n/a | 7 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $45 → $30 | $2.08 | n/a | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $272 → $326 | $939.68 | n/a | 4 | Feb 2, 2021 |
Ionis Pharmaceuticals
Jun 25, 2026
Maintained: Buy
Price Target: $100
Current: $81.80
Upside: +22.25%
Sangamo Therapeutics, Inc.
Jun 25, 2026
Rated: Hold
Price Target: n/a
Current: $0.0749
Upside: -
enGene Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: $2
Current: $1.78
Upside: +12.36%
Beam Therapeutics
Jun 4, 2026
Maintained: Buy
Price Target: $70
Current: $34.79
Upside: +101.21%
Intellia Therapeutics
May 12, 2026
Maintained: Hold
Price Target: $15
Current: $17.56
Upside: -14.58%
Metagenomi Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $12 → $9
Current: $1.26
Upside: +614.29%
Cytokinetics
May 7, 2026
Maintained: Buy
Price Target: $95 → $105
Current: $86.49
Upside: +21.40%
Sarepta Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $38
Current: $19.28
Upside: +97.10%
BeOne Medicines AG
May 7, 2026
Maintained: Buy
Price Target: $400
Current: $297.65
Upside: +34.39%
CRISPR Therapeutics AG
May 5, 2026
Maintained: Hold
Price Target: $75
Current: $60.08
Upside: +24.83%
Apr 14, 2026
Rated: Buy
Price Target: $50 → $90
Current: $86.63
Upside: +3.89%
Apr 2, 2026
Maintained: Buy
Price Target: $45
Current: $34.83
Upside: +29.20%
Mar 20, 2026
Maintained: Buy
Price Target: $11
Current: $6.53
Upside: +68.45%
Mar 11, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $13.65
Upside: +83.15%
Mar 10, 2026
Maintained: Hold
Price Target: $4
Current: $3.65
Upside: +9.59%
Mar 9, 2026
Upgraded: Buy
Price Target: $15 → $60
Current: $41.81
Upside: +43.51%
Mar 4, 2026
Maintained: Buy
Price Target: $20
Current: $7.28
Upside: +174.73%
Feb 25, 2026
Reiterated: Buy
Price Target: $14
Current: $4.31
Upside: +224.83%
Jan 14, 2026
Maintained: Buy
Price Target: $5
Current: $1.58
Upside: +216.46%
Jan 13, 2026
Maintained: Hold
Price Target: $4
Current: $3.30
Upside: +21.21%
Jan 5, 2026
Maintained: Hold
Price Target: $2.5
Current: $2.92
Upside: -14.38%
May 14, 2025
Downgraded: Hold
Price Target: $11 → $0.1
Current: $0.0001
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $1.5 → $1
Current: $0.039
Upside: n/a
May 6, 2025
Maintained: Buy
Price Target: $10
Current: $3.78
Upside: n/a
May 16, 2024
Rated: Hold
Price Target: n/a
Current: $37.93
Upside: n/a
Aug 16, 2023
Maintained: Hold
Price Target: $45 → $30
Current: $2.08
Upside: n/a
Feb 2, 2021
Maintained: Hold
Price Target: $272 → $326
Current: $939.68
Upside: n/a